In the same study, the CML cell line K562 was also used, and it was reported that MCL1 blockade increased the imatinib response in both sensitive and resistant cells (Aichberger et al. 2005). The gene discussed is MCL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.